Maryland State Retirement & Pension System Has $11.45 Million Stock Holdings in Abbott Laboratories $ABT

Maryland State Retirement & Pension System lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 4.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,163 shares of the healthcare product maker’s stock after acquiring an additional 3,275 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Abbott Laboratories were worth $11,447,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ABT. Hughes Financial Services LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter valued at $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter valued at $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories during the 1st quarter worth about $30,000. JCIC Asset Management Inc. acquired a new position in Abbott Laboratories during the 1st quarter worth about $32,000. Finally, Vision Financial Markets LLC acquired a new position in Abbott Laboratories during the 1st quarter worth about $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several recent research reports. Raymond James Financial cut their target price on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a report on Friday, July 18th. Morgan Stanley lifted their target price on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Evercore ISI lifted their target price on Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a report on Tuesday. BTIG Research cut their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, July 18th. Finally, Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $146.24.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $134.45 on Thursday. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The firm has a market capitalization of $234.00 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 2.52 and a beta of 0.69. The business has a 50-day simple moving average of $132.30 and a 200 day simple moving average of $131.48. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the company posted $1.14 EPS. The firm’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s payout ratio is presently 29.57%.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.46% of the stock is owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.